NanoBio to Present Preclinical Data on Its Nanoemulsion Adjuvanted Intranasal RSV Vaccine and Novel Inhaled Cystic Fibrosis Therapy at 52nd Annual ICAAC Meeting
ANN ARBOR, Mich. (September 10, 2012) – NanoBio Corporation announced today it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting currently underway in San Francisco.
The presentation details are as follows:
Poster Presentation: G-869 – “Comparison of β-propiolactone and W805EC Nanoemulsion for Inactivation of RSV Nasal Vaccination in a Mouse Challenge Model.”
Date: Monday, Sept. 10 at 11:15 a.m. – 1:15 p.m. Pacific Time
During the presentation, NanoBio will share preclinical data on its nanoemulsion adjuvanted intranasal Respiratory Syncytial Virus (RSV) vaccine which demonstrated immunogenicity and protection against challenge in mouse models, without the development of airway hyper-reactivity (AHR), which has plagued other RSV vaccine approaches.
RSV is a highly contagious disease affecting children and the elderly. It is the leading cause of childhood hospitalization in the U.S. and globally, and is a trigger of long-term asthma. Currently, there are no vaccines for RSV available today, despite tremendous need and widespread interest to develop new therapies.
NanoBio’s RSV vaccine uses nanoemulsion technology as an intranasal adjuvant and delivery system.
Poster Presentation: F-2070 – “A Novel Inhaled Anti-Infective Agent (NB-401) for Lung Infections: Estimating in vivo Airway Surface Liquid Concentrations in Humans.”
Date: Wednesday, Sept. 12, 9:15 – 11:15 a.m. Pacific Time
During the presentation, NanoBio will share preclinical data on its novel inhaled anti-infective agent, NB-401, which demonstrated in vitro activity against a broad spectrum of cystic fibrosis (CF) isolates, including difficult-to-treat pathogens such as burkholderia and methicillin-resistant Staphylococcus aureus (MRSA).
CF is a rare, but devastating chronic genetic lung disease affecting 75,000 people worldwide. CF is ranked as one of the most prevalent life-shortening diseases, with a median survival of approximately 37 years.
NB-401 is a novel, nanoemulsion-based inhalation treatment for CF, and potentially other respiratory infections.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.